GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Recordati SpA (OTCPK:RCDTF) » Definitions » Sale Of Investment

Recordati SpA (Recordati SpA) Sale Of Investment : $0 Mil (TTM As of Dec. 2023)


View and export this data going back to 2010. Start your Free Trial

What is Recordati SpA Sale Of Investment?

Recordati SpA's sale of investment for the three months ended in Dec. 2023 was $0 Mil. It means Recordati SpA gained $0 Mil from selling investments. Recordati SpA's sale of investment for the trailing twelve months (TTM) ended in Dec. 2023 was $0 Mil.

Compared with last quarter ($0 Mil in Sep. 2023 ), Recordati SpA gained the same money from selling investments in Dec. 2023 ($0 Mil).

Recordati SpA Sale Of Investment Historical Data

The historical data trend for Recordati SpA's Sale Of Investment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Recordati SpA Sale Of Investment Chart

Recordati SpA Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Sale Of Investment
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Recordati SpA Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Sale Of Investment Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Recordati SpA Sale Of Investment Calculation

Sale of Investments represents cash inflow on the sale of investments in securities.

Sale Of Investment for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Recordati SpA Sale Of Investment Related Terms

Thank you for viewing the detailed overview of Recordati SpA's Sale Of Investment provided by GuruFocus.com. Please click on the following links to see related term pages.

Recordati SpA (Recordati SpA) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Recordati SpA (OTCPK:RCDTF) » Definitions » Sale Of Investment
Comparable Companies
MIL:AGAIN MIL:VNT MIL:CIRC MIL:RETI MIL:DGV MIL:FOS MIL:AIW MIL:XPR MIL:NRST MIL:TNXT LLY JNJ MRK ABBV LSE:AZN XSWX:NOVN XSWX:ROG AMGN PFE XPAR:SAN
Traded in Other Exchanges
RICFY:USA REC:Italy RECm:UK 0KBS:UK RER1:Germany
Address
Via Matteo Civitali 1, MIlan, ITA, 20148
Website
https://www.recordati.com
Recordati SpA is a drug manufacturing company that focuses on specialty pharmaceuticals. The company produces and promotes medicines globally that focus on primary-care therapies and rare diseases. Recordati uses strategic partnerships as part of its long-term growth. The vast majority of the company's revenue is generated in Italy, followed by the United States, France, and Germany. Recordati reports two operating segments: Specialty and Primary care and Rare diseases. The bulk of the company's profit is derived from its specialty and primary care segment, which includes the production of active ingredients.

Recordati SpA (Recordati SpA) Headlines

From GuruFocus

ARS Pharmaceuticals and Recordati Announce Exclusive License for the Rights in Europe and additional countries for Neffy� (ARS-1; epinephrine nasal spray)

By PRNewswire PRNewswire • 09-22-2020

Isturisa® Is Now Available as a Medical Treatment for Cushing's Syndrome in Germany

By Business Wire Business Wire • 07-16-2020

Recordati: Isturisa® (Osilodrostat) Approved In The U.S.

By PRNewswire PRNewswire • 03-09-2020

Recordati: Positive Results From the Phase III LINC-3 Study of Isturisa® (osilodrostat) for the Treatment of Cushing's Disease Published in Lancet Diabetes & Endocrinology

By Business Wire Business Wire • 07-28-2020

Recordati Rare Diseases Announce Publication of Long-term Outcomes From the Extension to the Phase III LINC 3 Study of Isturisa� (Osilodrostat) in Patients With Cushing's Disease in the European Journal of Endocrinology

By Business Wire Business Wire • 08-31-2022

Recordati Rare Diseases: Isturisa® (osilodrostat) Phase III LINC-4 Trial Meets Its Primary Endpoint in Cushing's Disease

By Business Wire Business Wire • 06-17-2020

Recordati Rare Diseases Announce Publication in the Journal of Clinical Endocrinology & Metabolism of the Phase III LINC 4 Study Confirming the Efficacy and Safety of Isturisa� (Osilodrostat) in Patients With Cushing's Disease

By Business Wire Business Wire • 03-29-2022

Recordati Rare Diseases Announces First European Launch of Isturisa® (osilodrostat)

By Business Wire Business Wire • 06-02-2020